Rob Tighe

• Structural differentiation: Unlike head-to-tail bispecifics, OTP-01 is a standard effector-null IgG1 that possesses a unique dual-paratopic Fab with overlapping binding sites that co-engage PD-1 and VEGFR2 in a single arm
• Functional differentiation: Leveraging a standard IgG1 backbone, OTP-01 potently and cooperatively engages both targets to enhance tumor biodistribution, while simultaneously neutralizing – VEGF-A/C/D signalling to optimally remodel the TME and curb resistance
• Clinical trajectory: OTP-01 is now in IND-enabling studies, with IND submission targeted for late 2025

As PD-1 x VEGF and PD-L1 x VEGF bispecifics progress through preclinical and early clinical pipelines, developers are

challenged to refine therapeutic design, clarify mechanisms of synergy, and anticipate translational hurdles. This roundtable will bring together expert voices and engaged attendees to explore what it will take to successfully advance the bispecific and other bispecifics using similar logic to clinical impact.

• How can target biology guide decisions on bispecific format, affinity tuning, and spatial delivery?
• What insights and programs help us define meaningful biomarkers and pharmacodynamic readouts?
• How can we rationally combine these bispecifics with other immunotherapies or modalities like ADCs and cytokines?
• What are the biggest translational blind spots (e.g., preclinical models) holding back predictive development?
• How do we de-risk safety in multitargeting strategies, especially when soluble and membrane-bound targets are involved?